NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on

developing minimally disruptive surgical products and procedures for

the spine, announced today that the Company will participate in

several investor events in May 2012.

As part of its Medical Supplies & Devices Southern California Bus

Tour, Barclays Capital will host a group of investors at NuVasive's

headquarters in San Diego, CA, on Thursday, May 10, 2012, at 10:00

a.m. PDT.

Patrick F. Williams, Vice President of Strategy and Investor

Relations, is scheduled to present at the Bank of America Merrill

Lynch Health Care Conference at the Encore at the Wynn Hotel in Las

Vegas, NV, on Tuesday, May 15, 2012, at 10:00 a.m. PDT.

As part of its West Coast Healthcare Bus Tour, RBC Capital Markets

will host a group of investors at NuVasive's headquarters in San

Diego, CA, on Tuesday, May 22, 2012, at 1:00 p.m. PDT.

A live webcast of each event will be available online from the

investor relations page of the Company's corporate website at

After the live webcast, a replay will remain available on the website

for 30 days.

About NuVasive NuVasive is a medical device company focused on

developing minimally disruptive surgical products and procedurally

integrated solutions for the spine. The Company is the 5th largest

player in the $7.6 billion global spine market.

NuVasive's principal product offering is based on its Maximum Access

Surgery, or MAS@ platform. The MAS platform combines several

categories of solutions that collectively minimize soft tissue

disruption during spine surgery with maximum visualization and safe,

easy reproducibility for the surgeon: a proprietary software-driven

nerve avoidance system and intra-operative monitoring support;

MaXcess@, a unique split-blade retractor system; a wide variety of

specialized implants; and several biologic fusion enhancers. MAS

significantly reduces surgery time and returns patients to activities

of daily living much faster than conventional approaches. Having

redefined spine surgery with the MAS platform's lateral approach,

known as eXtreme Lateral Interbody Fusion, or XLIF@, NuVasive has

built an entire spine franchise. With over 70 products today spanning

lumbar, thoracic and cervical applications, the Company will continue

to expand and evolve its offering predicated on its R&D focus and

dedication to outstanding service levels supported by a culture of

Absolute Responsiveness@.

NuVasive cautions you that statements included in this press release

that are not a description of historical facts are forward-looking

statements that involve risks, uncertainties, assumptions and other

factors which, if they do not materialize or prove correct, could

cause NuVasive's results to differ materially from historical results

or those expressed or implied by such forward-looking statements. The

potential risks and uncertainties that could cause actual growth and

results to differ materially include, but are not limited to: the

uncertain process of seeking regulatory approval or clearance for

NuVasive's products or devices, including risks that such process

could be significantly delayed; the possibility that the FDA may

require significant changes to NuVasive's products or clinical

studies; the risk that products may not perform as intended and may

therefore not achieve commercial success; the risk that competitors

may develop superior products or may have a greater market position

enabling more successful commercialization; the risk that additional

clinical data may call into question the benefits of NuVasive's

products to patients, hospitals and surgeons; and other risks and

uncertainties more fully described in NuVasive's press releases and

periodic filings with the Securities and Exchange Commission.

NuVasive's public filings with the Securities and Exchange Commission

are available at

NuVasive assumes no obligation to update any forward-looking statement

to reflect events or circumstances arising after the date on which it

was made.